Stockscreener 앱 받기
4.63
1.49%
-0.07
전일 마감가:
$4.70
열려 있는:
$4.7
하루 거래량:
3,249
Relative Volume:
0.08
시가총액:
$5.77M
수익:
$12.99M
순이익/손실:
$-27.83M
주가수익비율:
-0.0227
EPS:
-203.7366
순현금흐름:
$-26.98M
1주 성능:
-2.73%
1개월 성능:
-2.94%
6개월 성능:
-76.62%
1년 성능:
-92.97%
1일 변동 폭
$4.63
$4.70
1주일 범위
$4.59
$4.88
52주 변동 폭
$3.80
$235.98
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.63 | 5.86M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
449.98 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.70 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.45 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.08 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.60 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
| 2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate
APVO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces HeadwindsPretax Income Report - newsline.com
Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan
Aptevo names Mary Janatpour as chief scientific officer - Investing.com UK
Aptevo Therapeutics Names Mary Janatpour Chief Scientific Officer as It Expands Beyond Core Immuno-Oncology Programs - citybiz
Aptevo names Mary Janatpour as chief scientific officer By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer - ACCESS Newswire
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Black Hills Pioneer
Seattle biotech lands investment, collaboration deal for cancer treatments - The Business Journals
Aptevo and Niowave Partner to Develop Radiopharmaceuticals; Niowave to Invest in Aptevo - geneonline.com
Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave - TipRanks
Aptevo Therapeutics (APVO) Forms Strategic Collaboration with Ni - GuruFocus
APVO Q1 2026 Earnings: EPS Miss Widens as Revenue Remains AbsentEarnings Preview - The Legal Advocate
Aptevo and Niowave launch radiopharmaceuticals collaboration - The Pharma Letter
Aptevo, Niowave form 50/50 partnership for cancer drugs By Investing.com - Investing.com Nigeria
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, I - PharmiWeb.com
Aptevo, Niowave form 50/50 partnership for cancer drugs - Investing.com
Niowave takes 7.9% Aptevo stake in cancer radiopharma tie-up - Stock Titan
APVO Q1 2026 Earnings: Stock Rises Despite Wider-Than-Expected Loss as Pipeline Progress Takes Center Stage - The Legal Advocate
APVO Q1 2026 Earnings: Stock Gains Sharply Despite Wider-Than-Expected LossShare Dilution Risk - The Legal Advocate
Aptevo (APVO) Q1 2026 Earnings: Soft Quarter Raises QuestionsEarnings Miss Alert - Newser
All you need to know about Aptevo Therapeutics (APVO) rating upgrade to buy - MSN
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy - Yahoo Finance
Aptevo (APVO) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Consistency Score - Newser
Key facts: Aptevo Q1 loss $0.01/sh; mipletamig shows 87% clinical benefit - TradingView
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports clinical trial results for AML drug candidate By Investing.com - Investing.com India
Aptevo (APVO) Positioned for Growth with Promising Pipeline and Leadership - GuruFocus
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo Therapeutics (NASDAQ: APVO) warns on going concern after $6.7M Q1 loss - Stock Titan
Strong AML data and $60M equity facility in Aptevo (NASDAQ: APVO) Q1 update - Stock Titan
Aptevo Therapeutics Updates on Q1 2026 Progress and Leadership T - GuruFocus
Aptevo reports clinical trial results for AML drug candidate - Investing.com UK
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - ACCESS Newswire
Leukemia trial hits 81% remission; Aptevo lines up $60M equity line - Stock Titan
APVO Price Today: Aptevo Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
TradingKey - TradingKey
Number of shareholders of Aptevo Therapeutics, Inc. – GETTEX:AP82 - TradingView
10-K - SEC.gov
Aptevo Therapeutics Inc expected to post a loss of $5.60 a shareEarnings Preview - TradingView
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
자본화:
|
볼륨(24시간):